Quince Therapeutics Shares Plunge 90% After Disappointing Phase 3 Trial Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 30 2026
0mins
Should l Buy QNCX?
Source: Benzinga
- Trial Results: Quince Therapeutics' NEAT clinical trial failed to meet its primary endpoint, with mean changes of 0.94 in the active group versus 2.24 in the placebo group, resulting in a difference of -1.30 and a p-value of 0.0851, leading to a nearly 90% plunge in stock price.
- Participant Demographics: The trial enrolled a total of 105 participants, including 83 children aged 6 to 9 and 22 aged 10 and older, indicating challenges in clinical research for rare diseases that may impact future funding and R&D plans.
- Safety Profile: Although eDSP was generally well tolerated with no clinically meaningful safety concerns, common adverse events like pruritus and pyrexia could affect patient adherence to treatment, potentially leading to negative market acceptance.
- Long-term Treatment Data: Data presented at the British Paediatric Neurology Association indicated that long-term treatment with eDSP in children with A-T showed no corticosteroid-related growth suppression; however, the trial failure may undermine investor confidence in the company's future products.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy QNCX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on QNCX
Wall Street analysts forecast QNCX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for QNCX is 7.00 USD with a low forecast of 5.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.146
Low
5.00
Averages
7.00
High
10.00
Current: 0.146
Low
5.00
Averages
7.00
High
10.00
About QNCX
Quince Therapeutics, Inc. is a late-stage biotechnology company. The Company is engaged in unlocking the patient’s own biology to deliver life-changing therapeutics to those living with rare diseases. Its proprietary autologous intracellular drug encapsulation (AIDE) technology platform is a drug/device combination that uses an automated process designed to encapsulate a drug into the patient’s own red blood cells. The Company’s Phase III lead asset, eDSP, leverages its AIDE technology to encapsulate dexamethasone sodium phosphate (DSP) into a patient’s own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, Ataxia-Telangiectasia (A-T). Its AIDE technology is designed to allow for the chronic administration of drugs that have limitations due to toxicity, poor biodistribution, suboptimal pharmacokinetics, or immune response. The AIDE technology platform delivers a variety of therapeutics, ranging from small to large molecules drugs and biologics.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, including upgrades, downgrades, and initiations, reflecting varying market perspectives that could influence investor decisions.
- Market Reaction: While specific company names are not mentioned, analyst rating changes typically attract market attention, prompting investors to adjust their positions based on these ratings, which can lead to stock price volatility.
- Impact of Rating Changes: Adjustments in analyst ratings not only affect short-term stock prices but can also influence a company's long-term investment appeal, especially in times of heightened market uncertainty when investors rely more on professional analysts' opinions.
- Further Information: For a complete view of all analyst rating changes, including specific upgrades, downgrades, and initiations, investors are encouraged to visit the analyst ratings page to make more informed investment decisions.
See More
Quince Therapeutics Shares Plunge 90% After Disappointing Phase 3 Trial Results
- Trial Results: Quince Therapeutics' NEAT clinical trial failed to meet its primary endpoint, with mean changes of 0.94 in the active group versus 2.24 in the placebo group, resulting in a difference of -1.30 and a p-value of 0.0851, leading to a nearly 90% plunge in stock price.
- Participant Demographics: The trial enrolled a total of 105 participants, including 83 children aged 6 to 9 and 22 aged 10 and older, indicating challenges in clinical research for rare diseases that may impact future funding and R&D plans.
- Safety Profile: Although eDSP was generally well tolerated with no clinically meaningful safety concerns, common adverse events like pruritus and pyrexia could affect patient adherence to treatment, potentially leading to negative market acceptance.
- Long-term Treatment Data: Data presented at the British Paediatric Neurology Association indicated that long-term treatment with eDSP in children with A-T showed no corticosteroid-related growth suppression; however, the trial failure may undermine investor confidence in the company's future products.
See More
Quince's Clinical Trial Fails to Meet Key Endpoints
- Trial Results Disappoint: Quince's late-stage trial involving 105 patients with Ataxia-Telangiectasia failed to meet its primary endpoint, indicating a lack of statistical significance in treatment efficacy, prompting the company to cease clinical development of its lead asset.
- Stock Price Plummets: Following the announcement of the trial failure, shares of Quince Therapeutics, Inc. (QNCX) closed down 92% on Thursday, reflecting extreme investor pessimism regarding the company's future prospects.
- Market Reaction: Despite the significant drop in stock price, QNCX shares saw a slight 2% increase in after-hours trading, indicating some investor optimism, particularly as retail sentiment on Stocktwits shifted from 'neutral' to 'bullish' over the past 24 hours.
- Industry Context: Ataxia-Telangiectasia is a rare inherited neurodegenerative disorder with no approved therapies globally, despite approximately 4,600 diagnosed patients in the U.S., highlighting a significant unmet medical need in this area.
See More
Quince Therapeutics Reports Phase 3 Trial Results for A-T Treatment
- Trial Results: Quince Therapeutics announced topline results from its pivotal Phase 3 NEAT trial for Ataxia-Telangiectasia (A-T), where the active group showed a mean change of 0.94 compared to 2.24 in the placebo group among 105 participants, failing to achieve statistical significance (p=0.0851), indicating limited treatment efficacy.
- Safety Profile: While eDSP was generally well tolerated during the trial, common adverse events included pruritus and pyrexia, with no clinically meaningful safety concerns identified, providing a foundation for future therapeutic options.
- Patient Transition to OLE: Nearly all participants (except one) opted to transition to the company's open-label extension study after completing the treatment period, reflecting sustained interest and potential long-term efficacy expectations from patients.
- Market Potential: With approximately 4,600 diagnosed A-T patients in the U.S. and an estimated 5,000 in the U.K. and EU4 countries, the current lack of approved treatments highlights the potential demand for eDSP in the future market.
See More
Quince Therapeutics' Clinical Trial Fails to Meet Primary Endpoint
- Clinical Trial Results: Quince Therapeutics' NEAT trial failed to achieve statistical significance on its primary endpoint, with mean changes from baseline to six months of 0.94 in the active arm versus 2.24 in the placebo arm, resulting in a difference of -1.30 and a p-value of 0.0851, indicating limited treatment efficacy.
- Key Secondary Endpoint Failure: The trial also did not meet its key secondary endpoint for Clinical Global Impression of Severity (CGI-S), with a p-value of 0.522, further demonstrating that eDSP did not meet efficacy expectations.
- Development Plan Halted: In light of the disappointing results, the company has decided to cease clinical development of eDSP, aiming to preserve cash and explore available options, which may impact future R&D investments and market strategy.
- Patient Population Context: Ataxia-Telangiectasia (A-T) is a rare genetic neurodegenerative disorder, with approximately 4,600 diagnosed patients in the U.S.; the failure of Quince's eDSP treatment underscores the unmet therapeutic needs and market opportunities in this area.
See More
Quince Completes A-T Phase 3 Trial, Expects Results in Q1 2026
- Clinical Trial Milestone: Quince Therapeutics announced the completion of the last patient visit in its pivotal Phase 3 NEAT clinical trial, with topline results expected in mid-Q1 2026, marking a significant advancement in the treatment of rare diseases.
- Efficient Design: Conducted under a Special Protocol Assessment with the U.S. FDA, the trial was powered at approximately 90% for treatment difference, and maintained low rates of discontinuation, enhancing the probability of success and demonstrating the company's rigor in clinical research.
- Patient Engagement: The NEAT study enrolled a total of 105 participants, with 83 in the primary analysis cohort aged 6 to 9 years, and nearly all participants opted to transition to the open-label extension study, reflecting high recognition and trust in the treatment among patients.
- Technological Innovation: The eDSP system utilizes Quince's proprietary AIDE technology to encapsulate drugs in the patient's own red blood cells, aiming to improve drug tolerability and biodistribution, potentially offering new treatment options for A-T patients and filling a significant market gap.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, including upgrades, downgrades, and initiations, reflecting varying market perspectives that could influence investor decisions.
- Market Reaction: While specific company names are not mentioned, analyst rating changes typically attract market attention, prompting investors to adjust their positions based on these ratings, which can lead to stock price volatility.
- Impact of Rating Changes: Adjustments in analyst ratings not only affect short-term stock prices but can also influence a company's long-term investment appeal, especially in times of heightened market uncertainty when investors rely more on professional analysts' opinions.
- Further Information: For a complete view of all analyst rating changes, including specific upgrades, downgrades, and initiations, investors are encouraged to visit the analyst ratings page to make more informed investment decisions.
See More
Quince Therapeutics Shares Plunge 90% After Disappointing Phase 3 Trial Results
- Trial Results: Quince Therapeutics' NEAT clinical trial failed to meet its primary endpoint, with mean changes of 0.94 in the active group versus 2.24 in the placebo group, resulting in a difference of -1.30 and a p-value of 0.0851, leading to a nearly 90% plunge in stock price.
- Participant Demographics: The trial enrolled a total of 105 participants, including 83 children aged 6 to 9 and 22 aged 10 and older, indicating challenges in clinical research for rare diseases that may impact future funding and R&D plans.
- Safety Profile: Although eDSP was generally well tolerated with no clinically meaningful safety concerns, common adverse events like pruritus and pyrexia could affect patient adherence to treatment, potentially leading to negative market acceptance.
- Long-term Treatment Data: Data presented at the British Paediatric Neurology Association indicated that long-term treatment with eDSP in children with A-T showed no corticosteroid-related growth suppression; however, the trial failure may undermine investor confidence in the company's future products.
See More
Quince's Clinical Trial Fails to Meet Key Endpoints
- Trial Results Disappoint: Quince's late-stage trial involving 105 patients with Ataxia-Telangiectasia failed to meet its primary endpoint, indicating a lack of statistical significance in treatment efficacy, prompting the company to cease clinical development of its lead asset.
- Stock Price Plummets: Following the announcement of the trial failure, shares of Quince Therapeutics, Inc. (QNCX) closed down 92% on Thursday, reflecting extreme investor pessimism regarding the company's future prospects.
- Market Reaction: Despite the significant drop in stock price, QNCX shares saw a slight 2% increase in after-hours trading, indicating some investor optimism, particularly as retail sentiment on Stocktwits shifted from 'neutral' to 'bullish' over the past 24 hours.
- Industry Context: Ataxia-Telangiectasia is a rare inherited neurodegenerative disorder with no approved therapies globally, despite approximately 4,600 diagnosed patients in the U.S., highlighting a significant unmet medical need in this area.
See More
Quince Therapeutics Reports Phase 3 Trial Results for A-T Treatment
- Trial Results: Quince Therapeutics announced topline results from its pivotal Phase 3 NEAT trial for Ataxia-Telangiectasia (A-T), where the active group showed a mean change of 0.94 compared to 2.24 in the placebo group among 105 participants, failing to achieve statistical significance (p=0.0851), indicating limited treatment efficacy.
- Safety Profile: While eDSP was generally well tolerated during the trial, common adverse events included pruritus and pyrexia, with no clinically meaningful safety concerns identified, providing a foundation for future therapeutic options.
- Patient Transition to OLE: Nearly all participants (except one) opted to transition to the company's open-label extension study after completing the treatment period, reflecting sustained interest and potential long-term efficacy expectations from patients.
- Market Potential: With approximately 4,600 diagnosed A-T patients in the U.S. and an estimated 5,000 in the U.K. and EU4 countries, the current lack of approved treatments highlights the potential demand for eDSP in the future market.
See More
Quince Therapeutics' Clinical Trial Fails to Meet Primary Endpoint
- Clinical Trial Results: Quince Therapeutics' NEAT trial failed to achieve statistical significance on its primary endpoint, with mean changes from baseline to six months of 0.94 in the active arm versus 2.24 in the placebo arm, resulting in a difference of -1.30 and a p-value of 0.0851, indicating limited treatment efficacy.
- Key Secondary Endpoint Failure: The trial also did not meet its key secondary endpoint for Clinical Global Impression of Severity (CGI-S), with a p-value of 0.522, further demonstrating that eDSP did not meet efficacy expectations.
- Development Plan Halted: In light of the disappointing results, the company has decided to cease clinical development of eDSP, aiming to preserve cash and explore available options, which may impact future R&D investments and market strategy.
- Patient Population Context: Ataxia-Telangiectasia (A-T) is a rare genetic neurodegenerative disorder, with approximately 4,600 diagnosed patients in the U.S.; the failure of Quince's eDSP treatment underscores the unmet therapeutic needs and market opportunities in this area.
See More
Quince Completes A-T Phase 3 Trial, Expects Results in Q1 2026
- Clinical Trial Milestone: Quince Therapeutics announced the completion of the last patient visit in its pivotal Phase 3 NEAT clinical trial, with topline results expected in mid-Q1 2026, marking a significant advancement in the treatment of rare diseases.
- Efficient Design: Conducted under a Special Protocol Assessment with the U.S. FDA, the trial was powered at approximately 90% for treatment difference, and maintained low rates of discontinuation, enhancing the probability of success and demonstrating the company's rigor in clinical research.
- Patient Engagement: The NEAT study enrolled a total of 105 participants, with 83 in the primary analysis cohort aged 6 to 9 years, and nearly all participants opted to transition to the open-label extension study, reflecting high recognition and trust in the treatment among patients.
- Technological Innovation: The eDSP system utilizes Quince's proprietary AIDE technology to encapsulate drugs in the patient's own red blood cells, aiming to improve drug tolerability and biodistribution, potentially offering new treatment options for A-T patients and filling a significant market gap.
See More
